These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1984 related items for PubMed ID: 27003417

  • 1. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [Abstract] [Full Text] [Related]

  • 2. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
    Wu KY, Liu CY, Chen CS, Chen CH, Hsiao IT, Hsieh CJ, Lee CP, Yen TC, Lin KJ.
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
    [Abstract] [Full Text] [Related]

  • 3. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y.
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [Abstract] [Full Text] [Related]

  • 4. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M, Peter J, Wintering NA, Serruya M, Shamchi SP, Werner TJ, Alavi A, Newberg AB.
    J Alzheimers Dis; 2019 May; 70(4):1197-1207. PubMed ID: 31322568
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging.
    Ottoy J, Niemantsverdriet E, Verhaeghe J, De Roeck E, Struyfs H, Somers C, Wyffels L, Ceyssens S, Van Mossevelde S, Van den Bossche T, Van Broeckhoven C, Ribbens A, Bjerke M, Stroobants S, Engelborghs S, Staelens S.
    Neuroimage Clin; 2019 May; 22():101771. PubMed ID: 30927601
    [Abstract] [Full Text] [Related]

  • 11. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies.
    Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, Kung MP, Lin KJ.
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):613-20. PubMed ID: 22270508
    [Abstract] [Full Text] [Related]

  • 12. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL, AIBL Research Group.
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [Abstract] [Full Text] [Related]

  • 13. Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET.
    Hsiao IT, Huang CC, Hsieh CJ, Wey SP, Kung MP, Yen TC, Lin KJ.
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):908-20. PubMed ID: 23412134
    [Abstract] [Full Text] [Related]

  • 14. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
    Bailly M, Ribeiro MJ, Vercouillie J, Hommet C, Gissot V, Camus V, Guilloteau D.
    Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
    [Abstract] [Full Text] [Related]

  • 15. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
    Chiotis K, Carter SF, Farid K, Savitcheva I, Nordberg A, Diagnostic Molecular Imaging (DiMI) network and the Alzheimer’s Disease Neuroimaging Initiative.
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F, Mariano-Goulart D, Payoux P, Alzheimer’s Disease Neuroimaging Initiative (ADNI).
    J Alzheimers Dis; 2018 Sep; 62(1):399-408. PubMed ID: 29439345
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 3D-SSP analysis for amyloid brain PET imaging using 18F-florbetapir in patients with Alzheimer's dementia and mild cognitive impairment.
    Thientunyakit T, Sethanandha C, Muangpaisan W, Minoshima S.
    Med J Malaysia; 2021 Jul; 76(4):493-501. PubMed ID: 34305110
    [Abstract] [Full Text] [Related]

  • 20. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
    King-Robson J, Wilson H, Politis M, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2021 Jul; 82(2):541-560. PubMed ID: 34057079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 100.